Trial · NCT05230901
Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden
NCT05230901, Phase 3, Unknown, University Medical Center Goettingen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden. Trials, record NCT05230901. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05230901
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden
- NCT number
- NCT05230901
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 300 participants, estimated
- Lead sponsor
- University Medical Center Goettingen
- Conditions
- Aortic Stenosis, Severe
- Interventions
- Standard of Care, Spironolactone 25mg, Dihydralazine
- First posted
- 2022-02-09
- Last updated
- 2022-06-28
Source ClinicalTrials.gov
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Extracellular volume (ECV)-derived matrix volume (measured by CMR) | 12 months | Differences between treatment groups in reduction of extracellular volume (ECV)- derived matrix volume (measured by CMR) after 12 months |
| Secondary | Left ventricular ejection fraction | 12 months | Differences in recovery of left ventricular ejection fraction (EF) in % (measured by CMR) after 12 months |
| Secondary | Global longitudinal strain | 12 months | Differences in recovery of global longitudinal strain (GLS) in % (measured by CMR) after 12 months |
| Secondary | diastolic function | 12 months | Differences in recovery of diastolic function (measured by CMR) after 12 months |
| Secondary | Left ventricular myocardial tissue volumes | 12 months | Differences in reduction of left ventricular myocardial tissue volumes (measured by CMR) after 12 months |
| Secondary | Left ventricular blood volumes | 12 months | Differences in reduction of left ventricular blood volumes (measured by CMR) after 12 months |
| Secondary | Kansas City Cardiomyopathy Questionnaire | 12 months | Differences in quality of life changes according to 23-items Kansas City Cardiomyopathy Questionnaire (KCCQ) after 12 months |
| Secondary | NYHA status | 12 months | Differences in NYHA status after 12 months |
| Secondary | 6min-walking test distance (6MWT) | 12 months | Differences in 6min-walking test distance (6MWT; in m) after 12 months |
| Secondary | NT-proBNP-levels | 12 months | Differences in NT-proBNP-levels (in pg/ml) after 12 months |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05230901
GET https://conductscience.org/api/trials/v1/NCT05230901/registered?page=2